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Abstract
Alzheimer’s disease (AD) is an incurable, progressive neurodegenerative disorder and 
the most common type of dementia. Although four kinds of drugs are currently available 
for AD, these are symptomatic treatments and do not halt disease progression. Therefore, 
there is an urgent need for development of curative drugs for AD. Amyloid plaques are 
the main disease hallmark observed in AD brains. As amyloid-β (Aβ) is a major constitu-
ent of amyloid plaques, Aβ has been supposed to be pathogenic for AD (amyloid hypoth-
esis). Thus, current, mainstream AD drug development is based around this hypothesis. 
In particular, both active and passive immunotherapies are aggressively employed. 
However, most clinical trials based on this hypothesis, including immunotherapies, failed 
to improve cognitive impairment in AD. Therefore, it is likely that AD onset is caused 
by factors besides Aβ. We have previously demonstrated that the intracellular domain 
of amyloid precursor protein (AICD) induces dynamic changes in gene expression and 
neuron-specific apoptosis, probably related to AD pathogenesis. Therefore, AICD may be 
a favorable target for AD therapies. In this chapter, current trials for AD therapies, espe-
cially immunotherapies targeting Aβ, are summarized. In addition, therapies targeting 
tau, another possible pathogenic molecule, are also described. Furthermore, we discuss 
the possibility of AICD as a novel therapeutic target for AD.
Keywords: Alzheimer’s disease (AD), immunotherapy, amyloid precursor protein 
(APP), the intracellular domain of APP (AICD), tau, signaling
1. Introduction
Alzheimer’s disease (AD) is an age-onset, incurable, neurodegenerative disorder and the most 
common form of dementia in elderly people worldwide. This disease presents as progressive 
memory loss, accompanied by cognitive impairment and behavioral abnormalities, caused 
by neuronal dysfunction and cell death of neurons. At present, only four kinds of drugs are 
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approved for the treatment of AD, all of which act as modulators of abnormal neurotransmit-
ter systems: three cholinesterase inhibitors (donepezil, rivastigmine and galantamine) [1] and 
one N-methyl-D-aspartic (NMDA) glutamate receptor antagonist (memantine) [2]. Low levels 
of acetylcholine and dysfunction and loss of cholinergic neurons are observed in AD brains [3]; 
therefore, these cholinesterase inhibitors are thought to inhibit acetylcholine degradation, main-
tain it at high levels and restore the function of cholinergic neurons. NMDA glutamate receptors 
are excessively and continuously activated in AD brains, which may lead to memory disorder 
and excitotoxicity. Memantine, a NMDA receptor antagonist, suppresses this excessive activa-
tion and may improve cognitive function. These drugs are temporarily effective in improving 
cognitive function; however, they are symptomatic and unable to halt disease progression in 
AD. Therefore, there are currently many trials of curative treatments for AD underway.
Although current understanding of AD etiology is not sufficient for development of AD 
therapies, two pathological hallmarks are commonly observed in AD brains and thought to 
be related to AD pathogenesis: extracellular amyloid plaques, consisting of amyloid-β (Aβ) 
and intracellular neurofibrillary tangles, consisting of hyperphosphorylated tau proteins. Aβ 
peptide, a major constituent of amyloid plaques in AD, is generated from amyloid precursor 
protein (APP) through stepwise, proteolytic cleavage by β- and γ-secretases. Mutations not 
only in APP [4], but also in presenilin (PS) 1 [5] and PS2 [6, 7], both of which are catalytic 
subunits of γ-secretase complex, are known to be responsible for early onset familial AD 
(FAD). These mutations accelerate proteolysis of APP and accumulation of Aβ, leading to the 
formation of amyloid plaques. Therefore, it is generally believed that Aβ is a causative factor 
in AD, called the amyloid hypothesis [8, 9], and this forms the basis for current, mainstream 
AD drug development. Additionally, tau, a microtubule-associated protein, is thought to 
be another pathogenic agent and potential therapeutic target for AD. Tau proteins stabilize 
microtubules, and hyperphosphorylated tau disperses and destabilizes microtubules, poten-
tially resulting in neurodegeneration.
Immunotherapy is a disease treatment designed to modulate an immune response against 
certain target molecule(s) and is widely used in a variety of diseases, such as cancers, auto-
immune diseases and allergies [10]. In the field of AD, immunotherapies, especially those 
designed based on amyloid hypothesis, have been aggressively employed [11]. Other thera-
peutic approaches, including inhibition of β- and/or γ-secretases to reduce Aβ production, 
have mostly failed, so immunotherapies targeting Aβ have been much anticipated as curative 
treatments, and many clinical trials have been attempted. Although both active and passive 
immunotherapies, againsnt various species of Aβ, have been designed and tested in clinical 
trials, most of these trials have not met endpoints in terms of improving survival or cogni-
tive impairment, even in the cases with marked clearance of amyloid plaques [12]. Recently, 
immunotherapies against tau have also been attempted [13]. Although neurofibrillary tangles 
are formed within neurons, and the mechanisms by which intracellular pathogenic tau pro-
teins can be excluded/neutralyzed by immunotherapies are not fully elucidated, these thera-
pies are also expected to improve AD symptoms.
As outlined above, current mainstream AD drug development is based on the amyloid 
hypothesis. However, almost all trials targeting Aβ, including immunotherapies, have 
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failed to show efficacy in AD patients. Although genetic linkage analyses in FAD indicate 
that mutations in APP, PS1 and PS2 genes are linked to increased APP proteolysis and Aβ 
secretion, other fragments are also generated during the proteolysis of APP. For instance, 
extracellular fragments of APP are produced by β-secretase cleavage, and subsequent 
γ-secretase cleavage generates the intracellular domain (ICD) of APP (AICD) at the same 
time as Aβ. It is likely that these APP-derived fragments other than Aβ, contribute to AD 
pathogenesis [14].
γ-Secretase was originally identified as an APP-cleaving enzyme [15]. Although its biological 
roles are not fully characterized, γ-secretase is known to play a critical role in the regulation 
of Notch signaling [16, 17]. In canonical Notch signaling, γ-secretase cleaves Notch within its 
transmembrane domain to release the ICD of Notch (NICD), which immediately translocates 
to the nucleus and modulates expression of target genes through transcription factor binding. 
It was recently reported that many type-1 transmembrane proteins, besides APP and Notch, 
are substrates for γ-secretase, [18, 19] and their resultant ICDs can be detected in the nucleus. 
These observations suggest that the role of γ-secretase is to generate ICDs from its substrates 
to act as transcription factors [20–23]. Indeed, we have demonstrated that AICD alters the 
expression of a broad range of genes, leading to neuron-specific apoptosis, probably associ-
ated with AD pathogenesis [24, 25]. Based on these results, we propose that AICD may be a 
novel therapeutic target for AD [26].
In this chapter, current trials for AD therapies based on the amyloid hypothesis, especially 
immunotherapies against Aβ, are summarized. Other therapies, including immunotherapies 
against tau, are also described. Furthermore, we discuss the possibility of AICD as a novel 
therapeutic target for AD.
2. Aβ and amyloid hypothesis
APP plays a key role in AD pathogenesis [27, 28], although its physiclogical function has 
not been fully elucidated [29]. As previously described, because of the formation of amyloid 
plaques as one of the major hallmarks in AD, their main constituent, Aβ, is believed to be 
pathogenic.
Aβ is generated from APP through two stepwise enzymatic cleavages (Figure 1(a)). During 
the proteolytic process, APP is initially cleaved at either the α-site or the β-site, within its 
juxtamembrane domain, by α-secretase or β-secretase, respectively. Subsequently, both 
resultant membrane-tethered stubs are further cleaved at the γ-site and ε-site within the 
transmembrane domain by γ-secretase, resulting in the secretion of a non-amyloidogenic 
p3 fragment (in combination with α-secretase) or an amyloidogenic Aβ fragment (in com-
bination with β-secretase). In both scenarios, AICD is simultaneously released from the 
cell membrane into the cytoplasm by γ-secretase cleavage. As mutation of APP, PS1 or PS2 
genes in FAD accelerates proteolytic processing of APP and increases levels of Aβ, the amy-
loid hypothesis is believed to best explain the pathogenic mechanism of AD, and is the basis 
for most AD drug development.
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3. Secretase inhibitors
Several drugs to decrease and/or remove pathogenic Aβ and amyloid plaques have been 
developed. As Aβ is generated through proteolysis by β-secretase and γ-secretase, inhibitors 
for these enzymes were developed to decrease Aβ production [30].
β-Secretase is a type 1 transmembrane aspartic acid protease, also known as β-site APP cleav-
ing enzyme 1 (BACE1). As human BACE1 knock-in mice showed accumulation of Aβ and, in 
an early study, BACE1-deficient mice did not display any abnormal phenotype, BACE1 inhibi-
tors were expected to be safe therapeutic drugs for AD [31, 32]. LY2886721 was the first BACE1 
inhibitor to reach Phase 2 clinical trials, but it was terminated due to liver toxicity [33]. Although 
other BACE1 inhibitors, such as MK-8931 and E2609, have been developed, and some are cur-
rently in clinical trials [34], recent studies have demonstrated that there are putative substrates 
for β-secretase besides APP [35], and adverse effects due to the inhibition of cleavage of these 
substrates should be of concern. In fact, further analyses of BACE1 knockout mice revealed 
several abnormal phenotypes such as axon guidance defects and hypomyelination [36]. Thus, 
it is likely that it will be difficult to inhibit the activity of β-secretase without side effects.
Inhibitors of γ-secretase (GSI) have also been developed to reduce levels of Aβ. Semagacestat 
was the first γ-secretase inhibitor to be taken into Phase 3 clinical trials; however, these trials 
were discontinued because patients showed worsened clinical measures of cognition and side 
effects such as increased risk of skin cancer and infections [37]. There are a large number of 
Figure 1. Proteolytic processing of APP and Notch. (a) After the cleavage of APP at the α-site or the β-site within its 
juxtamembrane domain by α-secretase or β-secretase, respectively, both remaining membrane-tethered stubs are further 
cleaved at the γ- and ε-sites within their transmembrane domains by γ-secretase. These sequential proteolytic reactions 
result in the secretion of either a non-amyloidogenic p3 fragment (α- and γ-secretase combination) or an amyloidogenic 
aβ peptide (β- and γ-secretase combination), and AICD (both combinations). (b) Notch is expressed on the cell surface 
as a heterodimer after cleavage at the S1 site by furin-like convertase. After the cleavage of Notch at the S2 site within 
its juxtamembrane domain by a metalloprotease, its remaining stub is further cleaved at the S3 and S4 sites within its 
transmembrane domain by γ-secretase, resulting in the production of NICD and Nβ fragment.
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membrane proteins that are substrates for γ-secretase [18, 19], and it is likely that GSIs will 
induce various adverse effects due to the inhibition of cleavage of other substrates, especially 
Notch. To date, GSIs that are selective for APP but not Notch (Notch-sparing GSIs) such as 
avagacestat, have been developed. Disappointedly, avagacestat failed to improve cognitive 
function and caused gastrointestinal and dermatological side effects [38].
γ-Secretase modulators (GSMs) are drugs that shift the γ-secretase cleaving site of APP and 
impair the production of the most toxic Aβ42 fragments, but do not affect other substrate 
cleavage. One such GSMs, tarenflurbil, was tested in Phase 3 clinical trials, but did not show 
beneficial effects in AD patients [39]. Recently, meta-analysis of pharmacological agents tar-
geting γ-secretase have shown that these drugs increase risk of cancer and cognitive decline 
in AD patients, indicating that γ-secretase may not be an appropriate target for clinical treat-
ment of AD [40].
4. Immunotherapies targeting Aβ
Besides the development of inhibitors for β- and γ-secretases, alternative attempts based 
on amyloid hypothesis have been made to remove soluble and/or insoluble Aβ utilizing 
immune responses. The first clinically relevant trial of immunotherapy directed towards 
Aβ was an active immunization using PDAPP transgenic mice, which overexpress mutant 
human APP with a valine to phenylalanine mutation at position 717 (V717F) under the con-
trol of a platelet-derived growth factor (PDGF) promoter. These transgenic mice, which 
exhibit accumulation of Aβ deposits at the age of 8–10 months, were immunized with Aβ, 
inducing high titers of Aβ-specific antibodies, resulting in the reduction and prevention of 
Aβ deposits [41, 42]. Based on these results, similar effects and clinical benefits were expected 
in human AD patients.
Active immunization with Aβ was the first immunotherapy performed in AD patients, who 
received full-length synthetic Aβ42 with QS-21 as the adjuvant (AN1792) [43–46]. A Phase 1 
study demonstrated good safety and tolerability of this immunization. However, in Phase 
2a, aseptic meningoencephalitis occurred in approximately 6% of AD patients treated with 
AN1792, probably due to a strong Th1 response, resulting in the termination of this trial [47]. 
Furthermore, follow-up assessments of the Phase 1 AN1792 study 6 years after immuniza-
tion revealed that there was no evident difference in cognitive decline between the treatment 
group and the placebo group, although postmodern pathological studies of some of the 
treated patients showed marked clearance of amyloid plaques in the brain [48]. In addition, 
follow-up of the Phase 2a trial 4.6 years after immunization reported no significant difference 
in the majority of cognitive assessments between AN1792-treated and placebo groups [49].
To avoid an inflammatory T cell response, Aβ1–6 peptide, which is derived from the N-terminal 
Aβ-specific B cell epitope, coupled to a bacteriophage QB protein coat, was employed as an 
immunogen for active immunotherapy (CAD106). Phase 1 trials showed induction of anti-Aβ 
antibodies, safety and tolerability of this immunization, and no incidence of meningoenceph-
alitis [50]. The Phase 2/3 clinical trial of CAD106 is currently ongoing.
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ACC-001 is a conjugate of multiple short N-terminal Aβ fragments (Aβ1–7), coupled to inac-
tivated diphtheria toxin as a carrier. In two Phase 2 trials, ACC-001 was administered with 
or without QS-21 adjuvant to patients with mild to moderate AD [51]. ACC-001 administered 
with QS-21 elicited higher peak and sustained anti-Aβ IgG titers compared with ACC-001 
alone. Exploratory cognitive evaluations did not show any difference or trends between treat-
ment groups and placebo groups, and this immunotherapy was discontinued from clinical 
development.
A number of other active immunotherapies have being developed, such as ACI-24, UB-311, 
ABvac40, and Lu AF20513 [52]. ACI-24 is a liposome vaccine against tetra-palmitoylated Aβ1–
15, which favors β-sheet structure, to induce antibodies specific to its conformation. UB-311 is 
a vaccine against Aβ1–14, formulated with CpG oligonucleotides and aluminum salt, which 
preferentially stimulates a Th2 regulatory response over a Th1 proinflammatory response. 
ABvac40 is a vaccine against multiple repeats of short Aβ C-terminus that is conjugated to 
keyhole limpet hemocyanin (KLH) and formulated with aluminum hydroxide. Lu AF20513 
is a vaccine developed against three repeats of Aβ1–12 peptides interspersed with P30 and P2 
T-cell epitopes of tetanus toxin to overcome weak immune response in the elderly by utilizing 
immunological memory generated by tetanus vaccination in childhood. These active immu-
notherapies are currently in the process of undergoing their respective clinical trials.
Although active immunotherapies are potentially cost-effective for long-term treatments, there 
are some limitations to this type of treatment. In elderly individuals over 65 years old, immune 
responses are generally weaker than in younger individuals, meaning active immunization 
may not induce sufficient production of antibodies specific for Aβ. In addition, active immuni-
zation could potentially induce autoreactive and/or unintended immune responses associated 
with severe adverse events, including the aseptic meningoencephalitis observed in AD patients 
treated with AN1792. Direct administration of passive immunotherapies, utilizing ready-made 
antibodies specific for Aβ, may be able to overcome these problems, if the Aβ-specific antibod-
ies have no, or reduced, cross-reactivity to self-antigens. To this end, several human/human-
ized monoclonal antibodies (mAb) against various epitopes of Aβ have been developed for 
passive immunization. Generally, the N-terminus of Aβ is exposed when it forms aggregates, 
while its middle and C-terminal regions are not accessible for antibodies. Thus, it is likely that 
mAbs specific for Aβ N-terminus are effective for the removal of Aβ aggregates, and those spe-
cific for Aβ mid-regions or C-terminus are effective for prevention of aggregation and exclu-
sion of monomeric Aβ. Two mechanisms have been suggested to explain the reduction of Aβ 
induced by mAbs [53, 54]: microglia activation through Fc receptors and the peripheral sink 
effect. Microglia are activated by administration of the mAb, through binding to the Fc recep-
tor, and can recognize and clear amyloid plaques. The peripheral sink effect hypothesizes that 
there is a decrease of soluble Aβ in the circulation due to binding of mAb to Aβ that alters the 
equilibrium of Aβ between the brain and the periphery and might draw Aβ out of the brain.
Bapineuzumab is a humanized immunoglobulin (Ig) G1 of murine mAb 3D6, which recog-
nizes the N-terminus of Aβ (Aβ1–5). This mAb binds fibrillar and soluble Aβ, and activates 
Fc receptor-mediated, microglial phagocytosis of Aβ deposits. Although some clearance of 
fibrillar Aβ was observed upon analysis with [11C]-Pittsburgh compound B and positron emis-
sion tomography (PET) in a Phase 2 study [55], two large Phase 3 studies of bapineuzumab 
showed no clinical benefits [56], and these trials were terminated.
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Solanezumab is a humanized monoclonal IgG1 of a murine mAb clone, m266, which binds 
the middle region of Aβ (Aβ16–26). This mAb recognizes soluble monomeric Aβ, not fibrillar 
Aβ. In two Phase 3 trials, solanezumab was administered to patients with mild to moderate 
AD, and no improvement on the primary endpoints was detected in these trials overall [57]. 
In contrast, subgroup analyses based on disease severity (mild or moderate) showed slowing 
of cognitive and functional decline in pooled mild AD patients [58]. However, in the next 
Phase 3 trial in patients with mild AD, solanezumab did not meet the primary endpoint and 
was abandoned as a treatment for mild AD [59].
Gantenerumab is a fully human IgG1, recognizing a conformational epitope on Aβ fibrils which 
encompasses both the N-terminal and middle regions of Aβ. Gantenerumab is thought to act 
mainly to disassemble and degrade amyloid plaques by supporting phagocytosis of microglia. 
In a Phase 3 study, no differences in efficacy measures were observed, and this clinical trial was 
stopped based on interim analysis for futility [60]. Despite the lack of a clinical benefit in sub-
jects overall, gantenerumab showed a beneficial trend in the fastest progressors, especially with 
higher serum levels of gantenerumab, on post hoc subgroup analysis. Further Phase 3 clinical 
trials employing dose titration schemes are planned, and the degree of amyloid reduction and 
cognitive improvement by administration of high doses of gantenerumab will be assessed.
Crenezumab is a humanized mAb that recognizes multiple aggregated forms of Aβ, including 
its oligomers, fibrils and amyloid plaques. Its affinity for Aβ monomers is lower. This mAb uses 
an IgG4 backbone to activate microglial phagocytosis and to minimize inflammatory responses 
related to side effects, such as vasogenic edema. Phase 2 trials of crenezumab showed no clinical 
benefits at its endpoints. However, a post hoc subgroup analysis of the high dose group sug-
gested that treatment with crenezumab attenuated cognitive decline in the milder subgroups. The 
Phase 3 trial of crenezumab in prodromal to mild AD patients at higher doses is in progress [61].
Aducanumab is a fully human IgG1 mAb generated from memory B cell libraries of healthy, 
aged individuals by screening for reactivity against aggregated Aβ. It is thought that immune 
systems of these donors without AD symptoms may be able to prevent AD, and that their anti-
bodies can assist in removal of amyloid plaques. Aducanumab interacts with the N-terminal 
region (Aβ3–6) of aggregated Aβ, including soluble oligomers and insoluble fibrils, but not 
monomers. In a Phase 1b clinical trial, florbetapir (18F) PET scans showed marked reduction 
of brain fibrillar Aβ in a dose- and time-dependent manner [62]. In addition, although this 
Phase 1b trial was not sufficient to detect clinical changes, exploratory analyses of clinical 
assessments revealed dose-dependent slowing of disease progression at 1 year. Based on 
these interim analyses, two identical Phase 3 trials were launched to evaluate the efficacy of 
aducanumab for slowing cognitive decline in patients with prodromal to mild AD.
BAN2401 is a humanized IgG1 mAb that selectively recognizes a specific conformation of 
large, insoluble Aβ protofibrils. A Phase 1 study of BAN2401 demonstrated its safety and 
tolerability [63], initiating a Phase 2 trial to evaluate its efficacy against cognitive impairment.
Ponezumab is a humanized IgG2 mAb that binds to the C-terminal region of Aβ (Aβ33–40). 
Although Phase 1 studies of ponezumab showed sufficient safety [64, 65], its Phase 2 trials 
revealed no significant cognitive improvement in patients with mild to moderate AD [66]. The 
development of ponezumab for AD was discontinued, although it is still in Phase 2 trials for 
cerebral amyloid angiopathy (CAA).
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Several other mAbs for Aβ have also been developed, with some of their clinical trials cur-
rently in progress. In addition to these passive immunotherapies, another strategy of passive 
immunization is currently being investigated. Pooled human plasma antibodies are prepared 
from donated blood and administered intravenously to AD patients (IVIg). These prepara-
tions contain a small fraction of naturally occurring polyclonal anti-Aβ antibodies and are 
expected to result in Aβ clearance and/or prevention of Aβ aggregation. Several of these IVIg 
preparations, such as gammagard and gamunex, are currently being administered to AD 
patients in clinical trials. A Phase 3 study of gammagard, observed no beneficial effects despite 
a significant decrease in plasma Aβ levels [67]. Clinical trials of other IVIgs are still in progress.
Although most passive immunotherapies targeting soluble and/or insoluble Aβ have entirely 
failed to show clear beneficial effects in patients with mild to moderate AD, Phase 3 clinical 
trials of solanezumab suggested that earlier intervention with this drug during the disease 
course may provide beneficial effects [58]. Although Phase 3 trials of solanezumab in mild AD 
patients did end in failure, administration of solanezumab and gantenerumab in asymptom-
atic and very mildly symptomatic carriers of autosomal-dominant mutations in APP, PS1 or 
PS2 genes, as well as cognitively healthy subjects at risk of developing sporadic AD, is being 
tested as a secondary prevention method [68]. In addition, crenezumab is also being tested in 
presymptomatic carriers of the E280A mutation in the PS1 gene [69].
Thus, there are no drugs based on amyloid hypothesis, including immunotherapies targeting 
Aβ, that show clear efficacy in AD patients to date, although some clinical and prevention 
trials are still in progress. These results may suggest the necessity of approaches other than 
targeting Aβ to develop efficacious treatments for AD.
5. Therapies against tau
In addition to extracellular amyloid plaques, intracellular neurofibrillary tangles are gener-
ally observed in AD patients as another histopathological hallmark of AD brains, and may 
be linked to AD pathogenesis. Pathological neurofibrillary tangles are aggregates of paired 
helical filaments composed of hyperphosphorylated tau. Tau is a microtubule-associated pro-
tein and binds to microtubules through its C-terminal assembly domain, thereby stabilizing 
microtubules and promoting microtubule polymerization. In the brains of AD patients, tau 
proteins are abnormally hyperphosphorylated by several protein kinases, such as glycogen 
synthetic kinase-3 β (GSK3β). Hyperphosphorylated tau proteins are detached from micro-
tubules due to their reduced affinity for tubulins, resulting in destabilization of cytoskeletal 
microtubules and the formation of neurofibrillary tangles. Thus, the hyperphosphorylated 
tau protein is thought to be another favorable target molecule for AD therapy.
Several compounds to inhibit hyperphosphorylation or aggregation of tau have been devel-
oped. Tideglusib is a small molecule that acts as an inhibitor of GSK3β and counteracts tau 
phosphorylation. In a Phase 2 trial tideglusib was reported to produce no clinical benefit in 
patients with mild to moderate AD [70]. Rember is a first generation drug designed to prevent 
tau aggregation and/or dissolve existing aggregates. It is a formulation of methylthioninium 
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chloride, known as methylene blue. Its second generation, TRx0237, a stabilized, reduced 
form of methylthioninium chloride, was developed to improve drug absorption. Phase 3 trials 
of TRx0237 are currently underway [71]. Several microtubule stabilizers, such as epothiline D 
and TPI287, have also been developed as AD drugs to counteract microtubule destabilization 
by tau hyperphosphorylation. Epothiline D has been discontinued for AD and TPI287 is in 
Phase 1 trials [72].
6. Immunotherapies targeting tau
Various forms of pathogenic tau proteins may also become targets for immunotherapies. Two 
mechanisms for recognition of intracellular tau proteins/neurofibrillary tangles by anti-tau 
antibodies have been proposed. First, pathogenic tau proteins are supposed to be propagated 
from one cell to the next. Experiments with P301S transgenic mice, which express human 
mutant P301S tau, causing inherited frontotemporal dementia and development of filamen-
tous tau inclusions, revealed that injection of brain extracts from P301S mice into the brains of 
wild-type human tau-expressing mice induced assembly of wild-type tau into filaments [73]. 
This pathological abnormality spread from the injection site to adjacent regions, suggesting 
extracellular transmission of tauopathy between cells. If certain pathological forms of tau can 
spread and induce abnormal assembly of normal tau in AD brains, it is therefore expected 
that anti-tau antibodies could bind to tau outside of cells and prevent the spread of tauopa-
thy, resulting in the inhibition of disease progression. Second, anti-tau antibodies may be 
translocated inside neurons. It has previously been shown that neurons can take up anti-tau 
antibodies via clathrin-dependent low affinity FcγII/III receptors-mediated endocytosis and 
that these now-intracellular antibodies can bind to pathological tau within the endosomal-
lysosomal system, promoting the clearance of pathological tau [74]. Thus, immunotherapies 
against pathological tau are hoped to be efficacious as AD treatments, and several active and 
passive immunotherapies, targeting various forms of pathological tau, have been developed.
AADvac-1 is an active vaccine consisting of a synthetic tau peptide (amino acids 294–305) 
coupled to KLH that is a carrier, with aluminum hydroxide as an adjuvant. The short tau 
domain synthesized for this vaccine is essential for pathological tau-tau interaction. A Phase 1 
trial of AADvac-1 showed a good safety profile and excellent antibody response [75]. A Phase 
2 trial is currently in progress.
In another Phase 1 study, ACI-35, which is a liposome-based vaccine consisting of a synthetic 
tau peptide (amino acids 393–408) phosphorylated at S396 and S404, is being tested in patients 
with mild to moderate AD [76].
Several humanized anti-tau mAbs are currently being tested in clinical studies as passive 
immunotherapies against tau. RG7345 is a humanized mAb specific for the tau phospho-
epitope pS422, which is critical for binding to microtubules. Tau phosphorylated at S422 is 
prominent in early stages of AD and persists until late-stage disease, making it an attractive 
target for antibody therapeutics. RG7345 was tested in a Phase 1 trial but was subsequently 
discontinued [77].
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BIIB092 is a humanized IgG4 mAb specific to extracellular, N-terminal fragments of tau (eTau), 
originally isolated from neuronal cultures using induced pluripotent stem cells derived from 
FAD patients. Since eTau is supposed to be involved in the spread of tauopathy, BIIB092 is 
expected to neutralize eTau propagation. Phase 1 trials of this mAb showed a dose-dependent 
accumulation in serum and CSF and marked reduction of CSF eTau, and a Phase 2 trial is 
planned [76].
ABBV-8E12 is a humanized mAb that recognizes an aggregated, extracellular form of patho-
logical tau, and, thus, has the potential to stop or slow the propagation of tau pathology 
observed in AD and other tauopathies. Since a Phase 1 study showed an acceptable safety 
and tolerability profile of single doses, two Phase 2 trials to assess the efficacy and safety of 
multiple doses are in progress [76].
Although there have not yet been any successful clinical trials of immunotherapies targeting 
tau, many researchers have recently focused on the tau protein as a target molecule for AD treat-
ment because of the failure of most clinical trials based on the amyloid hypothesis. However, 
since both the mechanism of transmission of tauopathies among cells, and that of antibody-
uptake in neurons, have not fully been characterized, further studies to elucidate these mecha-
nisms will be required in order successfully to design immunotherapies targeting tau.
7. γ-Secretase-regulated signaling and AICD
Since amyloid plaques, a major histopathological hallmark observed in AD, are thought to be 
a pathogenic factor in AD, Aβ, a main constituent of amyloid plaques, has long been thought 
to be a prime therapeutic target for AD. However, as mentioned, no clinical trials targeting Aβ 
have shown any efficacy in terms of cognitive improvement in progressing AD to date, and it 
is likely that there may be another mechanism that leads to the onset of AD.
As described above, genetic mutations in genes coding APP, PS1 and PS2 cause early onset of 
FAD. Since these genes are all associated with APP processing and Aβ production, and amy-
loid plaques are observed in the brains of both FAD and sporadic AD patients, the amyloid 
hypothesis, that Aβ is toxic for neurons and pathogenic in AD, has been widely accepted. 
Although several clinical trials of drugs targeting Aβ, including immunotherapies, are still in 
progress, no trials to date have succeeded in improving cognitive decline and/or behavioral 
abnormalities, even in the cases with marked reduction of soluble and insoluble Aβ. In addi-
tion to the failures of these clinical trials, several questions regarding amyloid hypothesis in 
AD have been raised. For example, amyloid plaques are often detected in the brains of healthy 
elderly people with no AD symptoms [78]. In addition, Aβ-overexpressing transgenic mice 
did not show any neurodegeneration although these mice exhibited Aβ deposition mimick-
ing amyloid plaques observed in AD brains [79]. These observations suggest that Aβ has no 
neurotoxicity or pathogenicity in AD. Based on the FAD genetic analysis described above, it 
still seems likely that APP itself and/or its proteolysis contributes to AD pathogenesis, and it 
is possible that an APP-derived fragment other than Aβ, is the cause of AD [14].
γ-Secretase has been primarily characterized as an APP cleavage enzyme, and is thought to play a 
role in AD pathogenesis [15]. Although the physiological functions of this enzyme have not been 
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fully elucidated, it is well known that γ-secretase plays a central role in the regulation of Notch 
signaling (Figure 2) [16, 17]. In the canonical Notch signaling pathway, Notch is cleaved at its S2 
site within the juxtamembrane domain by metalloproteases after the binding of ligands on neigh-
boring cells to Notch. Subsequently, the remaining membrane-associated, C-terminal fragment 
is further cleaved at S3 and S4 sites within the transmembrane domain by γ-secretase, resulting 
in the release of the ICD of Notch (NICD) into the cytoplasm. NICD immediately translocates to 
the nucleus where it binds to a CSL transcription factor (CBF-1/RBP-jκ in mammals, Suppressor 
of Hairless in Drosophila, Lag-1 in Caenorhabditis elegans) [16, 80] and a mastermind-like (MAML) 
protein [81] to form a complex. In this process, a co-repressor in this complex is substituted with a 
co-activator, such as p300 and P/CAF [82], and the resultant complex induces expression of certain 
target genes such as Hes [83]. In this way, γ-secretase plays a regulatory role in Notch signaling.
Recently, many type-1 transmembrane proteins have been reported as substrates for γ-secretase 
[18, 19]. Interestingly, the proteolytic processing of some of these substrates, including APP, 
is very similar to that of Notch, and several of these ICDs have been detected in the nucleus. 
These observations suggest that some of these substrate proteins possess γ-secretase-regulated 
signaling mechanisms similar to Notch signaling [20–23]. Indeed, we have previously demon-
strated that Delta, a ligand of Notch, possesses a γ-secretase-regulated signaling mechanism 
similar to Notch [84]. The ICD of Delta acts as a transcription factor through binding to Smad, 
a transcription factor in the TGF-β/activin signaling pathway, and modulates expression of tar-
get genes. These findings indicate that γ-secretase functions as a signaling regulator by generat-
ing ICDs of substrate membrane proteins, which then act as transcription factors in the nucleus.
AICD is generated through a proteolytic process similar to NICD (Figure 1 (a) and (b)), and it 
is possible that APP has a γ-secretase-regulated signaling mechanism similar to Notch [20–23]. 
We have previously demonstrated that AICD may act as a transcriptional factor, leading 
to neurodegeneration potentially related to AD pathogenesis. To examine the function of 
AICD, we used a teratocarcinoma P19 cell line, which can differentiate into neurons through 
stimulation with all-trans retinoic acids (RA), overexpressing AICD (AICD/P19). Although 
undifferentiated AICD/P19 cells were morphologically the same as control P19 cells, induc-
tion of AICD/P19 cells into neurons caused neuronal cell death with characteristic features of 
apoptosis, while control P19 cells differentiated normally into neurons [24]. In addition, DNA 
Figure 2. Notch signaling. When Notch binds to its ligand, Notch is cleaved at the S2 site by metalloproteases. Then, 
its remaining stub on the membrane is further cleaved at the S3 and S4 sites by γ-secretase, resulting in the release of 
NICD into cytoplasm. Immediately, NICD translocates to the nucleus and binds to the CSL transcription factor and 
MAML. During this process, the co-repressor(s) (Co-R) dissociate from this complex and the co-activator(s) (Co-A) is 
recruited. Finally, the resultant NICD-complex promotes the transcription of target genes as an activator.
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microarray analyses with these cells revealed that AICD dramatically altered expression of 
numerous genes, possibly due to function of AICD as a transcription factor [25]. Although 
genes with altered expression were not directly related to the apoptotic cascade, it is likely 
that such dynamic alteration in the expression of many genes would disturb homeostasis in 
neurons, leading to neuron-specific apoptosis. Thus, AICD has a γ-secretase-regulated mech-
anism similar to Notch and may have potential as a therapeutic target in AD.
Figure 3 shows a diagram of APP signaling model. To prevent AICD-induced neurodegen-
eration, several strategies are possible: (1) reduction of AICD generation, (2) prevention of 
AICD translocation to the nucleus and (3) removal of AICD in the cytoplasm.
To reduce AICD generation, inhibitors of β- and/or γ-secretases would be an obvious choice. 
However, these enzymes have many substrates, and it is highly possible that inhibition of 
these other proteolytic reactions may induce an adverse reaction [18, 19, 35].
To translocate to the nucleus, AICD must bind to the adaptor protein Fe65 [85, 86], and it is likely 
that this binding is regulated by phosphorylation/dephosphorylation at T668 within AICD [87]. 
Phosphorylation of T668 interferes with the interaction between AICD and Fe65, and AICD is 
constitutively phosphorylated at T668, impairing its translocation to the nucleus. Phosphorylated 
AICD remains in the cytoplasm and is rapidly degraded by the proteasome and/or insulin-
degrading enzyme (IDE) [88], suggesting that AICD is not toxic in the brains of healthy individu-
als. When AICD is dephosphorylated by phosphatases, or kinase phosphorylation of AICD is 
decreased, non-phosphorylated AICD can bind to Fe65 and translocate to the nucleus where it 
may act as a transcriptional factor, leading to neuronal cell death [89]. Therefore, it is thought that 
drugs that can modulate AICD phosphorylation by either decreasing dephosphorylation activity 
or restoring/increasing phosphorylation activity on AICD, preventing its translocation into the 
nucleus, are potential future AD treatments. Alternatively, removal of cytoplasmic AICD prior 
to its nuclear translocation is another potential treatment avenue, and, in this regard, drugs that 
upregulate the activity of AICD degrading enzymes, such as IDE, may also be efficacious.
From an immunotherapy perspective, if anti-AICD antibodies can be taken up into neurons as 
described in the section of ‘Immunotherapies targeting tau’ [74], immunotherapies targeting 
AICD may also act to remove intracellular AICD and/or prevent its translocation to the nucleus.
Figure 3. APP signaling model. Most APP proteins on the membrane are phosphorylated at T668 within AICD in 
neurons. After the removal of APP ectodomain by α-secrease or β-secretase, AICD is released by γ-secretase from the 
cell membrane into the cytoplasm. Then, phosphorylated AICD stay in the cytoplasm and quickly degraded by the 
proteasome and/or insulin-degrading enzyme (IDE). Dephosphorylated AICD can bind to Fe65 and then translocate 
into the nucleus. In the nucleus, AICD/Fe65 complex further binds to the histone acetyltransferase Tip60, and acts as a 
transcriptional regulator for up- or downregulation of target genes.
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Thus, AICD may be a pathogenic agent in AD and has potential as a novel therapeutic target.
8. Conclusion
AD is an age-related, incurable, neurodegenerative disease and the most common type of 
dementia in elderly people. Increasing numbers of people suffer from this disease, but very 
few treatments are available, all of which are only symptomatic. Therefore, there is urgent 
need for development of curative AD therapies.
Although the precise mechanism underlying AD pathogenesis has not been elucidated, Aβ, 
a major constituent of amyloid plaques commonly observed in AD brains, is considered to be 
pathogenic. Most AD drugs have been designed in accordance with this ‘amyloid hypothesis’.
Based on the amyloid hypothesis, immunotherapy was expected to be a powerful approach 
to remove and decrease pathogenic Aβ, and many trials of both active and passive immuno-
therapies targeting Aβ have been attempted. However, these immunotherapies targeting Aβ 
have totally failed to show efficacy, even in cases with marked clearance of amyloid plaques. 
Therefore, Aβ may not be the pathogenic entity in AD. At present, several immunotherapies 
targeting another possible pathogenic agent, tau, are also being tested.
Since it is highly possible that an APP-derived fragment, probably one other than Aβ, is 
responsible for AD pathogenesis, we have focused on AICD. According to our observa-
tions, AICD induces neuron-specific apoptosis, and has potential as a therapeutic target in 
AD. Based on our findings, the most important step in designing a drug against AICD, is 
likely preventing its translocation to the nucleus. This step may also help to remove patho-
genic intracellular AICD. Taken together, it is hoped that AICD, and other promising target 
molecules, as well as Aβ and tau, will be further explored, and that efficacious treatments for 
AD will be established in the near future.
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